Granted Patent
B2
US 9,981,901 · App. 15/356,292 · Granted May 29, 2018
IRE-1α inhibitors
Inventors:
John B. Patterson (Ventura, CA); David G. Lonergan (San Marcos, CA); Gary A. Flynn (Tucson, AZ); Qingping Zeng (Thousand Oaks, CA); Peter V. Pallai (Carlsbad, CA)
Assignee:
FOSUN ORINOVE PHARMATECH, INC.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Compounds which directly inhibit IRE-1α activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies.
Claims (3)
1. An IRE-1α inhibitor, wherein the IRE-1α inhibitor is:
or a pharmaceutically acceptable salt thereof.
2. A pharmaceutical composition comprising the IRE-1α inhibitor of claim 1 .
Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Mar 22, 2018
From: SHANGHAI FOSUN PHARMACEUTICAL INDUSTRIAL DEVELOPMENT CO. LTD.
To: FOSUN ORINOVE PHARMATECH, INC.
Reel/Frame 045320/0357 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 23, 2017
From: MANNKIND CORPORATION
To: SHANGHAI FOSUN PHARMACEUTICAL INDUSTRIAL DEVELOPMENT CO. LTD.
Reel/Frame 042483/0622 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Apr 24, 2017
From: PATTERSON, JOHN B.; LONERGAN, DAVID G.; FLYNN, GARY A.; ZENG, QINGPING; PALLAI, PETER V.
To: MANNKIND CORPORATION
Reel/Frame 042322/0623 →
Continuity (6)
Provisional Application
60942743
· Jun 8, 2007